Prostate-specific membrane antigen (PSMA) has fundamentally reshaped prostate cancer imaging and therapy, delivering an unprecedented combination of high lesion conspicuity, broad clinical ...

Today’s common practice of empiric activity prescription in radiopharmaceutical therapy is inconsistent with the modern philosophy of personalized medicine. We investigate the radiobiologic ...

Prostate cancer is a rapidly expanding area for radiopharmaceutical therapy, primarily driven by prostate-specific membrane antigen–targeted imaging and therapy. This growth necessitates new workflows ...

Prostate cancer is one of the most prevalent malignancies in men and remains a leading cause of cancer-related morbidity and mortality worldwide. For many, prostate cancer follows an indolent course, ...

Journal of Nuclear Medicine Technology April 2026, jnmt.125.271114; DOI: https://doi.org/10.2967/jnmt.125.271114 ...

Journal of Nuclear Medicine Technology April 2026, jnmt.126.272015; DOI: https://doi.org/10.2967/jnmt.126.272015 ...

Journal of Nuclear Medicine Technology April 2026, jnmt.126.272276; DOI: https://doi.org/10.2967/jnmt.126.272276 ...

Journal of Nuclear Medicine Technology March 2026, jnmt.125.271409; DOI: https://doi.org/10.2967/jnmt.125.271409 ...

Journal of Nuclear Medicine Technology March 2026, jnmt.125.271050; DOI: https://doi.org/10.2967/jnmt.125.271050 ...

We report the cases of 3 patients with biopsy-proven light-chain cardiac amyloidosis (AL-CA) presenting with varying clinical manifestations and abnormal findings on Tc-based bone-avid scintigraphy, ...

The approval of disease-modifying antiamyloid therapies has expanded the clinical role of amyloid PET beyond diagnostic confirmation to include baseline characterization and longitudinal monitoring of ...